1 Followers
25 Following
chaitanyag11

chaitanyag11

Gene Therapy for Rare Disease Market is expected to witness a robust CAGR of 35.0%

The global gene therapy for rare disease market size was valued at US$ 16.3 million in 2017, and is expected to witness a robust CAGR of 35.0% over the forecast period (2018–2026).

In recent past, key players in the market have gained regulatory approvals and have launched their therapies in the market. Frequent approvals of novel gene therapies and their launches in the developed regions are expected to significantly drive gene therapy for rare disease market growth over the forecast period. For instance, in December 2017, Spark Therapeutics, Inc. received the U.S. Food and Drug Administration (FDA) approval for its LUXTURNA (voretigene neparvovec-rzyl), a one-time gene therapy product indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. Furthermore, in August 2018, Novartis International AG received European Commission’s (EC) approval for Kymriah (tisagenlecleucel, formerly CTL019) indicated for treatment of patients up to 25 years of age with relapse or refractory B-cell acute lymphoblastic leukemia (ALL) and for the treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. Moreover, in August 2018, Kite Pharma, Inc., a Gilead Company, received European Commission (EC) Marketing approval for its novel Yescarta (axicabtagene ciloleucel), as a treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy.

Download the PDF brochure:

https://www.coherentmarketinsights.com/insight/request-pdf/2321

Gene therapy involves insertion of genetic material into cells of the patients to provide new function or to restore missing or inappropriate functioning of the cells due to cancer or gene mutations. According to National Center for Advancing Translational Sciences, although around 7,000 rare diseases are identified, only a few hundred have approved treatments. Moreover, developing gene therapy for rare diseases is gaining significant traction, as more than 80% of rare diseases have a known monogenic (single-gene) cause. Small molecule drugs often treat symptoms only rather than curing underlying cause of the disease. This requires frequent administration of the drugs to manage the condition. Gene therapy holds the potential to correct underlying genetic defects. Moreover, a clinically sound and successful gene therapy may only require a single dose to cure a disease rather than requiring a lifetime treatment. Commercially approved gene therapies include Kymriah (Novartis AG), Yescarta (Gilead Sciences, Inc.), Luxturna (Spark Therapeutics), and Strimvelis (Orchard Therapeutics).

Presence of multiple novel gene therapies for various rare disease treatment in pipeline, which are expected to gain approval is expected to boost the market growth over the forecast period. For instance, Spark Therapeutics, Inc. is developing gene therapy namely Fidanacogene Elaparvovec, a novel, investigational gene therapy indicated for the treatment of patients suffering from hemophilia B. Currently, the therapy is under Phase 3 clinical trial and is expected to receive approval in near future. In August 2018, uniQure N.V. treated the first patient in its Phase IIb dose-confirmation study of AMT-061, an investigational AAV5-based gene therapy incorporating the FIX-Padua variant for the treatment of patients with severe and moderately severe hemophilia B. In May 2018, Orchard Therapeutics Plc. received Rare Pediatric Disease Designation from the U.S. Food and Drug Administration (FDA) for its gene therapy candidate OTL-200, indicated for treatment of patients with metachromatic leukodystrophy (MLD).  PTC Therapeutics, In. has GT-AADC in phase 3 clinical trials and is indicated for Aromatic L-Amino Acid Decarboxylase (AADC) deficiency.

Click To Reading More On Gene Therapy for Rare Disease Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Visit our news Website: https://www.coherentwire.com

Gene Therapy for Rare Disease Market is expected to witness a robust CAGR of 35.0%

In recent past, key players in the market have gained regulatory approvals and have launched their therapies in the market.

Postpartum Depression Drug Market Drivers,Regional Analysis And Growth

Signs of depression include, insomnia, fatigue and sadness, loss of appetite, mood swings, anxiety, and anger. Hormonal changes such as elevated prolactin levels, depleted oxytocin and thyroid hormone levels can be a cause of PPD in females.

Postpartum Depression Drug Market– Drivers

Increasing research activities for treatment of PPD is expected to propel growth of the postpartum depression drug market during the forecast period. For instance, Sage Therapeutics is undergoing phase 3 clinical study for the drug —Brexanolone, which might be useful in the treatment of PPD. The study started in May 2018 and is estimated to be completed in September 2020.

Furthermore, Marinus Pharmaceuticals, is undergoing clinical phase 2 study for the drug Ganaxolone in the treatment of PPD and other mood associated disorders. The clinical study started in June 2017 and is expected to be completed in June 2019.

Postpartum Depression Drug Market– Taxonomy

By Drug Class

Selective Serotonin Reuptake Inhibitors (SSRIs),Serotonin Norepinephrine Reuptake Inhibitors (SNRIs),Tricyclic Antidepressants,Atypical Antidepressants,Monoamine Oxidase Inhibitors (MAOIs)

By Distribution Channel

Hospital Pharmacies,Retail Pharmacies,Online Pharmacies

Get HOLISTIC Request Sample Copy Of This Business Report:

https://www.coherentmarketinsights.com/insight/request-sample/2258

Postpartum Depression Drug Market– Restraint

Antidepressant drugs refusals by the U.S. Food and Drug Administration (U.S FDA) are expected to be a major restraint in growth of the postpartum depression drug market over the forecast period. For instance, in April 2018, the U.S FDA refused New Drug Application of Alkermes plc.’s drug candidate ALKS 5461 which is to be administered orally. The drug could be useful in treating depressive disorders, which cannot be treated by other standard drug therapies. This refusal was due to failures in action of this oral medication.

Postpartum Depression Drug Market– Regional Analysis

On the basis of region, the global postpartum depression drug market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is estimated to hold dominant position in the global postpartum depression drug market during the forecast period, owing to increasing awareness of PPD. For instance, annually, May 2017 is celebrated as a National Maternal Depression Awareness Month recognizing the seriousness of depression during and after pregnancy in the U.S.

Furthermore, Asia Pacific is expected to witness significant growth in the global postpartum depression drug market during the forecast period, owing to increasing prevalence of PDD in the region. For instance, According to World Health Organization (WHO) July 2018 report, 22% of mothers in India suffer from PPD, annually.

Download the PDF brochure:

https://www.coherentmarketinsights.com/insight/request-pdf/2258

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Visit our news Website: https://www.coherentwire.com

Sulfachloropyridazine Sodium Market Drivers, Patient Type,Regional Analysis

Sulfachloropyridazine sodium is a sulfonamide antibiotic used to study kinetics and reaction pathways. Also, it is used to treat acute Urinary Tract Infections (UTIs) in pediatric patients. Sulfachloropyridazine sodium blocks the synthesis of dihydrofolic acid by inhibiting the enzyme dihydropteroate synthase and bacterial Para-Amino Benzoic Acid (PABA), which is required for bacterial growth. The compound Sulfachloropyridazine sodium powder has a curative effect for various animals with pasteurellosis and is popular for use in animal husbandry.

Sulfachloropyridazine Sodium Market Drivers

Rising use of antibiotics in animals to treat certain infections is expected to drive growth of the sulfachloropyridazine sodium market. For instance, according to an article published in journal Science, 2017, almost 80% of all antibiotics in the U.S. are administered to cows, pigs, and chickens to keep them healthy and accelerate their growth and development.

Moreover, according to the Louisiana Department of Health, U.S., due  to  low  cost  and  relatively better  efficacy against many common bacterial infections, sulfonamides  are  some  of  the  most common antibacterial agents utilized in veterinary medicine, which is in turn is boosting growth of the sulfachloropyridazine sodium market. 

Sulfachloropyridazine Sodium Market Restraint

Over the years, bacterial pathogens have acquired resistance to sulfonamide class of antibiotics, due to mutations in pre-existing DNA or by acquisition of Antibiotic Resistance Genes (ARGs), which is expected to hinder growth of the sulfachloropyridazine sodium market. For instance, according to an article published in journal Microbiome, 2017, use of sulfonamide class of antibiotics is restricted to topical use only extensively for animals.  For instance, in the U.S., around 380,186 kg of sulfonamides was distributed legally during 2015, to increase the resistance power of food-producing animals. Hence, further spread of sulfonamide resistance would have hamper the market particularly in the animal sector.

Get HOLISTIC Request Sample Copy Of This Business Report:

https://www.coherentmarketinsights.com/insight/request-sample/2263

Sulfachloropyridazine Sodium Market – Taxonomy

By Patient Type

Cows,Pigs,Chickens,Cattles,Pediatrics

By Region

North America,Europe,Asia Pacific,Latin America,Middle East,Africa

Sulfachloropyridazine Sodium Market – Regional Analysis

On the basis of region, the global sulfachloropyridazine sodium market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America region is expected to gain maximum share in the sulfachloropyridazine sodium market, owing to high prevalence of Urinary Tract Infections (UTIs) in the U.S. For instance, according to American Urological Association 2016, more than 1 million catheter-associated UTIs are reported annually in the U.S. and up to 40% of hospital gram negative bacteremias originate as UTIs annually, which are treated by antibiotics.

Asia Pacific region is expected to witness significant growth in the sulfachloropyridazine market due to involvement of key players in manufacturing antibiotics solely for veterinary purposes. One of the company named Weifang Premier Animal Pharmaceutical Industries Co., Ltd, a China-based company also involved in animal husbandry. They contributes to animal health by manufacturing sulfachloropyridazine sodium soluble powder as one of the key product in China.

Key players involved in Sulfachloropyridazine market include Sigma-Aldrich, Inc., Zhengzhou Fuyuan Chemical Industry Co., Ltd, Santa Cruz Biotechnology, Inc., UBM, Hefei TNJ Chemical Industry Co., Ltd., AK Scientific Inc., SuZhou Wugan Pharmaceutical Co., Quimica Alkano, Shanghai Danfan Network Science&Technology Co., Ltd., and Ofichem Group.

Click To Reading More On Sulfachloropyridazine Sodium Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Visit our news Website: https://www.coherentwire.com

Sulfachloropyridazine Sodium Market Drivers, Patient Type,Regional Analysis

Sulfachloropyridazine sodium is a sulfonamide antibiotic used to study kinetics and reaction pathways. Also, it is used to treat acute Urinary Tract Infections (UTIs) in pediatric patients. Sulfachloropyridazine sodium blocks the synthesis of dihydrofolic acid by inhibiting the enzyme dihydropteroate synthase and bacterial Para-Amino Benzoic Acid (PABA), which is required for bacterial growth. The compound Sulfachloropyridazine sodium powder has a curative effect for various animals with pasteurellosis and is popular for use in animal husbandry.

Arm/Leg Rest Industry: Study Growth Factors with Market Forecasts 2026

Placing the weight of arms on armrest reduces downward gravity acting on the spine and helps in improving posture, maintaining the integrity of the spine and intervertebral discs. Leg rests have an adjustable angle, which are removable and have calf pads that support lower part of the leg when elevated. Such features of arm/leg rest are helpful in spinal cord injury patients.

 

Arm/Leg Rest Market – Drivers

Research and development activities in arm/leg rest technology for the comfort of users is expected to propel growth of the arm/leg rest market. For instance, in 2018, Soarigami, developed a new, portable, and user friendly armrest device. Its stainless steel hardware adjusts to different arm widths with removable coverings and durability and facilitates its use in airplanes, trains, stadiums, and other places.

 

Get HOLISTIC Request Sample Copy Of This Business Report:

https://www.coherentmarketinsights.com/insight/request-sample/2222

 

Arm/Leg Rest Market – Restraint

Difficulty in moving and height adjustment are reducing user compliance, which in turn is expected to restrain growth of the arm/leg rest market. For instance, according to report published by United Spinal Association, 2017, armrest contains movable parts, which tend to get damaged. Wheelchair armrests may also at times interfere with wheelchair propulsion, making wheels more difficult to move.

 

Arm/Leg Rest Market – Regional Analysis

On the basis of region, the arm/leg rest market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected hold a dominant position in the global arm/leg rest market over the forecast period. This is owing to increasing prevalence of spinal cord injuries, which further result in arm and legs disabilities. For instance, according to Spinal Cord.com statistics, 2017, around 17,500 new spinal cord injuries are registered in the U.S., annually.

Furthermore, Europe is expected to witness significant growth in the arm/leg rest market, owing to new product launches. For instance, in March 2016, Yanfeng Automotive Interiors (YFAI), a Germany-based company, developed a new heated armrest for door panels of cars. Such armrest offers comfort, flexibility, and energy efficiency during winter.

Key players operating in the arm/leg rest market include, Inmoclinc s.a, Provita medical gmbh & co. kg., KOHLAS, Bristol Maid, Medi-Plinth, Cardinal Health, General Electric Company, and Better Mobility Ltd.

 

Click To Reading More On Arm/Leg Rest Industry

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

 

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Visit our news Website: https://www.coherentwire.com

Skull Clamp Market - Size, Share, Outlook, Global Insights

Skull Clamp Market – Restraint

Incidences of  injuries during usage of skull clamps is hampering the growth of skull clamp market. For instance, according to an article published in The Journal of the American Medical Association, (JAMA) 2016, skull clamp systems used in surgical procedures to immobilize the head and neck movement sometimes move or slip, leading to injuries such as skull fractures, facial cuts, and blood clots. This is hampering growth of the skull clamp market.

Skull Clamp Market – Regional Analysis

On the basis of region, the global skull clamp market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to hold dominant position in the skull clamp market, owing to increasing geriatric populations and increasing cases of brain injuries. For instance, according to a report published in The Morbidity and Mortality Weekly Report (MMWR) 2017, in the U.S., 153 people die due to traumatic brain injuries every day.

Get HOLISTIC Request Sample Copy Of This Business Report: https://www.coherentmarketinsights.com/insight/request-sample/2226

Asia Pacific is also expected to witness significant growth in the skull clamp market due to continuous foreign investments and less cost of spinal surgeries. For instance, according to data released by India Brand Equity Foundation on September 2018, healthcare has become one of India’s largest sectors both in terms of revenue and employment, and the cost of surgery in India is about one-tenth of that in the U.S. or Western Europe. Moreover, according to data released by the Department of Industrial Policy and Promotion (DIPP) 2018, the healthcare sector of India attracted Foreign Direct Investment (FDI) worth US$ 5.25 billion between April 2000 and June 2018.

Key players operating in the global skull clamp market include Allen Medical Systems, Inc., Barrfab, Eschmann Equipment, Medifa - Hesse GmbH & Co. KG, Schaerer Medical, TECHNOMED INDIA., OPT SURGISYSTEMS S.R.L., Micromar Ind. e Com. LTDA, pro med instruments, Inc., and Herbert.

Most neurosurgery procedures need rigid fixation of the head for successful operation. Skull clamps are indicated for such use in case of percutaneous craniotomies and spinal surgeries. They are placed on patient’s skull to hold their neck and head in proper posture during surgeries. Increasing number of neurosurgeries and development of new surgical techniques have led to demand for miniaturized instruments such as skull clamps to reduce post-surgical scars on body.

Skull Clamp Market – Drivers

Advancements in skull clamp technologies is expected to boost growth of the market. For instance, in October 2017, Mizuho OSI, a leading manufacturer of surgical equipment in the U.S., launched a new technology called Levo Head Positioning System at North American Spine Society (NASS), which will provide accurate head positioning during spine surgeries. It has various interchangeable modules, which supports efficient attachment to skull clamps providing safe and efficient patient care.

Click To Reading More On Skull Clamp Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

 

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Ostomy Care Market, by Device Type ,Opportunites,Growth,Trends And Global Insights

However, low awareness in underdeveloped and developing economies regarding the availability of treatments and increasing pricing pressure on the manufacturer is expected to confine the market growth.

Posterior Microsurgical Instruments Market – Regional Analysis,Trends, Outlook And Global Insights

Posterior Microsurgical Instruments Market – Driver

Organizing conferences and meetings by market players regarding posterior microsurgical are creating awareness amongst surgeons and patients, which is expected to drive growth of the market. For instance, Mercian Surgical Supply Co Ltd., company of U.K, is planning to exhibit a meeting for British Association of Spine Surgeons at Brighton, U.K., in April 2019, to discuss latest innovations in spinal surgeries.

Posterior Microsurgical Instruments Market – Restraint

The growth of global posterior microsurgical instruments market is depicted by the presence of various provincial and local vendors worldwide. This is creating huge competition for established players, as local vendors are providing such instruments at less cost, and thus hampering growth of the posterior microsurgical instruments market. Furthermore, according to a Sterilization and Infection Control Blog, October 2016, various surgical tools may remain inside the body post-surgery, causing harmful consequences among patients therefore, conducting further procedure become necessary, which in turn is expected to hamper growth of market.

Download the PDF brochure: https://www.coherentmarketinsights.com/insight/request-pdf/2225

Posterior Microsurgical Instruments Market – Regional Analysis

On the basis of region, the global posterior microsurgical instruments market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America region is expected to dominate the global posterior microsurgical instruments market due to adoption of inorganic growth strategies by key players such as agreements in the U.S. For instance, in April 2017, 7D Surgical System, entered into exclusive sales representative agreements with two premier American medical device distributors, Surgical One and DB Surgical, for Machine-Vision Image Guided Surgery (MvIGS) technology. This new MvIGS platform can achieve fast surgical workflow for spine procedures.

Asia Pacific region is expected to witness significant growth in posterior microsurgical instruments market due to rapidly growing healthcare sector and less cost of surgeries. For instance, according to data published by India Brand Equity Foundation (IBEF), in September 2018, the cost of surgery in India is about one-tenth of that in the US or Western Europe and healthcare has become one of India’s largest sectors both in terms of revenue and employment.

Furthermore, According to report published by IBEF 2017, government announced to open three medical devices parks including, The 200 acre park being established in India. Such advancements in healthcare infrastructure will provide opportunities for adoption of various surgical tools including posterior microsurgical instruments, in turn propelling growth of the market.

Key players operating in posterior microsurgical instruments market include Volk Optical Inc., Ziemer Ophthalmic Systems, Novartis AG, Carl Zeiss Meditec AG, Lumenis, Abbott laboratories, Katalyst Surgical, LLC. Mercian Surgical Supply Co Ltd., and Rumex International Co.

Click To Reading More On Posterior Microsurgical Instruments Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Visit our news Website: https://www.coherentwire.com

Posterior Microsurgical Instruments Market – Regional Analysis

The growth of global posterior microsurgical instruments market is depicted by the presence of various provincial and local vendors worldwide.

Tamoxifen Market: Regional Insights,Competitive Landscape,Opportunity Analysis 2026

Tamoxifen is a type of selective estrogen receptor modulator. The main pharmacologic action of Tamoxifen is to block the growth-promoting effects of estrogens on breast cancer. In bone cells, selective estrogen modulators interact with receptors the way estrogen does and strengthens bones. Tamoxifen is available in various forms such as powder, capsules, oral solution, and tablets.

Tamoxifen Market Dynamics

Being a generic molecule, the growth of the market has slowed down with increased competition. However, emergence of combination therapies and additional therapeutic indications for tamoxifen is expected to fuel the market growth. For instance, 2018 Novartis received breakthrough therapy designation for Kisqali by FDA in Phase 3. Designation was based on the successful phase 3 MONALEESA-7 trials, which demonstrated significant prolonged-free survival (PFS) of Kisqali + tamoxifen (or an aromatase inhibitor). Moreover, increasing number of government and non-government organizations are investing to discover additional therapeutic applications of tamoxifen, which in turn, is expected to boost market growth. For instance, In 2017 Duchenne UK, E-Rare, Duchenne Parent Project, and Monaco Association jointly contributed US$ 766,338 for a clinical trial, which aims to study the effects of tamoxifen in treating duchenne muscular dystrophy.

Tamoxifen Market – Competitive Landscape

Key players operating in the global tamoxifen market include Teva Pharmaceutical Industries Ltd, AstraZeneca plc, Aegis pharmaceuticals, Watson laboratories, Inc., Allergan plc, Mylan N.V., and Apotex Inc.Market players are focusing on adopting strategies such as acquisition and mergers to provide advanced research products to sustain their presence in the market. For instance, 2018 Dare Bioscience Inc. announced merger with Pear Tree Pharmaceuticals to procure rights to develop PT-101, as a potential treatment for vaginal and vulvar atrophy for patients suffering from hormone-receptive positive breast cancer. PT-101 is a proprietary vaginal formulation being developed by Pear Tree Pharmaceuticals.

Get PDF for more Professional and Technical insights@https://www.coherentmarketinsights.com/insight/request-sample/1801

Tamoxifen Market – Regional Insights

On the basis of region, the global tamoxifen market is segmented into North America, Europe, Latin America, Asia Pacific, Middle East, and Africa. North America tamoxifen market holds the dominant position, owing to high acceptance and high price of the drug in treating breast cancer. For instance, according to GoodRx Inc. 2018 pricing detail, 30 tablets of tamoxifen 20mg cost around US$ 65.71 on an average. Moreover, increasing prevalence of breast cancer has propelled the tamoxifen market growth in the North America region. According to 2018, U.S. Breast Cancer Organization statistics, around 1 in 8 U.S. women are estimated to develop invasive breast cancer during the course of her life. Moreover, around 266,120 women are expected to be diagnosed with invasive breast cancer in the U.S. in 2018.

Asia Pacific is expected to witness significant growth in the market over the forecast period, owing to its increasing number of people vulnerable to various chronic diseases and increasing healthcare initiatives. For instance, according to published article in the Lancet Oncology 2014, breast cancer is expected to rise from less than 60 cases per 100,000 woman aged 55-69 years to over 100 cases per 100,000 woman by 2021, reaching 2.5 million cases overall by 2021.

Tamoxifen is a type of selective estrogen receptor modulator (SERM) indicated for the treatment of women with high risk of breast cancer. Since its approval in 1998, tamoxifen has been used to treat millions of patients diagnosed with hormone receptor positive, early stage of breast cancer after surgery to reduce the risk of recurrence. It is the first choice for treatment of premenopausal women. Tamoxifen is the generic name for Nolvadex. Tamoxifen has off-label usage for the treatment of infertility, gynecomastia, retroperitoneal fibrosis, and idiopathic sclerosing mesenteritis.

 

Download the PDF brochure: https://www.coherentmarketinsights.com/insight/request-pdf/1801

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Visit our news Website: https://www.coherentwire.com

Breathing Machines Market Regional Insights,Competitive Landscape,Market Dynamics

Breathing Machines Market Regional Insights

On the basis of region, the global breathing machines market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold dominant position in the global breathing machines market in terms of revenue share, owing to increasing number of patients receiving treatments for respiratory diseases. According to COPD International, in 2016, around 12 million people in the U.S. were suffering from COPD and an estimated 12 million more were undiagnosed. According to a Centers for Disease Control and Prevention (CDC) report, it is the fourth leading cause of death in the U.S.

 

Asia Pacific breathing machines market is expected to exhibit highest CAGR, owing to continuously increasing number of surgeries and respiratory disease burden in the region. For instance, according to WHO 2017 report, over 90% of COPD deaths occur in low­ and middle-income economies. The primary cause of COPD is exposure to tobacco smoke. Other risk factors include exposure to indoor and outdoor air pollution and occupational fumes and dusts.

 

Breathing Machines Market: Competitive Landscape

Key players operating in the global breathing machines market include BD, Drager Medical, Fisher & Paykel, GE Healthcare, Invacare, Maque, Medtronic, OMRON, Philips Healthcare, Teijin Pharma Resmed, and Weinmann. Key players are focusing on improving breathing machines by developing energy-efficient power systems and product features such as lightweight maneuverability, long-lasting components, and patient-friendly design.

 

Get The Holistic SAMPLE Of This Business Report:

https://www.coherentmarketinsights.com/insight/request-sample/2032

Breathing machine helps the patient to breathe while they are suffering from chronic respiratory diseases or unable to breathe by themselves after anesthesia. Breathing machines are used during surgeries that require general anesthesia, as the medicines used to induce anesthesia can disrupt normal breathing. The machine is required after the surgery, as the patient may not be able to breathe immediately after the procedure. The type of breathing machine used varies according to the problem.

 

Ventilators are mainly used in emergency medicine, home care, intensive care medicine, and in anesthesia, as a component of an anesthesia machine. The oxygen concentrator delivers pure oxygen via a mask or nasal cannula. It may be used in hyperbaric chambers and oxygen therapy. A C-PAP (continuous positive airway pressure) breathing machine blows air into the nose through a mask, which in turn keeps the airway open and helps in the absorption of oxygen.

 

Breathing Machines Market Dynamics

Increasing number of respiratory disorders such as asthma and COPD, and rising number of surgeries are expected to drive growth of the global breathing machines market. According to the National Institute of Health data of 2014, asthma affects over 24 million people in the U.S., including over 6 million children. Breathing problems can also occur due to serious conditions such as pneumonia, tuberculosis, lung cancer, and other lung diseases. According to the World Health Organization (WHO) estimates, by 2030, the four major potentially fatal respiratory diseases including COPD, pneumonia, lung cancer, and tuberculosis will account for around one in five deaths worldwide.

 

Millions of people in the U.S. suffer from breathing problems such as chronic obstructive pulmonary disease (COPD), which includes chronic bronchitis and emphysema. COPD is a progressive life-threatening lung disease that causes breathlessness and predisposes to exacerbations and serious illness. In 2016, the Global Burden of Disease reported a prevalence of around 251 million cases of COPD worldwide. According to the same source, a total of 3.17 million deaths occurred due to COPD in 2015, which account for 5% of all deaths globally. COPD prevalence is expected to increase in the near future due to higher smoking prevalence and aging populations in many economies worldwide.

 

Click To Reading More On Breathing Machines Market

https://www.coherentmarketinsights.com/ongoing-insight/breathing-machines-market-2032

 

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

 

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Visit our news Website: https://www.coherentwire.com

Gene Therapy Market Trend, Growth, Outlook,Major Key Players And Market Analysis 2025

Gene Therapy Market – Dynamics

Demand for gene therapy is significantly increasing due to increasing number of patients suffering from hereditary disorders, cancer, HIV, and various chronic diseases. For instance, 2018 American Cancer Society report showed cancer was responsible for 609,640 deaths in the U.S. Moreover, in 2017, WHO reported 1.0 million deaths were caused due to HIV-related illnesses worldwide. Increasing technological developments, innovations, and clinical and pre-clinical trials. For instance, According to published article in 2014 Regenerative Medicine reports 4749 registries of clinical trials related to stem cell treatment. Several diseases are likely to propel growth of the gene therapy market size during the forecast period. Moreover, increasing research and development funding by government agencies and commercial market players for the development of innovative, efficient, and safer gene therapy practices is boosted the market growth. For instance, 2017 National Institutes of Health was funded US$ 1,644 million for stem cell research. Furthermore, growing awareness and community acceptance of gene therapy for various disease treatments is propelling growth of the market.

However, unwanted immune responses related to treatment, concerns regarding unethical use of gene therapy and high cost associated with the treatment can hamper the market growth.

Get PDF for more Professional and Technical insights@

https://www.coherentmarketinsights.com/insight/request-sample/1774

Genes are composed of deoxyribonucleic acid (DNA), which contains essential information for producing proteins that are crucial for the optimal functioning of the body. Genetic disorder is the result of gene mutations in which proteins are made incorrectly. Gene therapy is intended to introduce healthy gene into damaged cells to counteract for abnormal genes or to make a protein of interest. Mutated gene causes missing of the important protein, with the help of gene therapy normal copy of that missing or faulty protein can be introduced to restore the function of the protein. All over the world, gene therapy is being extensively studied by the researchers for the treatment of various diseases such as HIV, Cancer, Parkinson’s disease, hemophilia and even immune deficiencies through various approaches. For instance, According to 2015, article published in Journal Gene Technology and Resistance to Viruses has shown the future prospect of the bone marrow gene therapy for HIV treatment. Three primary approaches being practiced in the gene therapy are substituting a mutated gene with the healthier one, disabling a mutated gene that is functionally inappropriate and introducing a novel gene in the body to fight a disease. In the gene therapy treatment, vectors are responsible for insertion of functional gene into the genome of an individual tissues and cells, one of the most common vectors are viruses. The gene therapy treatment which was once considered as unfeasible, has now become a trend among small and big companies. Result of this has been an increased the in the number of various successful startups, backed by financiers in line with giant companies these have boosted the growth of the market.

Gene Therapy Market – Competitive Advances

Key players operating in the global gene therapy market include GlaxoSmithKline plc, Bluebird Bio, Inc., Adaptimmune Therapeutics plc, Celgene Corporation, Shanghai Sunway Biotech Co. Ltd., Merck KGaA, Transgene SA, and OncoGenex Pharmaceuticals, Inc. These companies are conducting various clinical and pre-clinical developmental stages of gene therapies. Key players are engaged in developing new technologies and are focusing on collaborating with leading companies in order to retain their foothold in the global market. For instance, in 2017, the U.S. Food and Drug Administration (FDA) approved a gene therapy called Luxturna, developed by Spark Therapeuticsa Biotech Company based in Philadelphia.

Download the PDF brochure:

https://www.coherentmarketinsights.com/insight/request-pdf/1774

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Visit our news Website: https://www.coherentwire.com

Poly Adenosine Diphosphate Ribose Polymerase Market By Drug Olaparib, Rucaparib, Niraparib By Region Latin America, Europe

Cancer is one of the most prevalent fatal chronic disorders with a high mortality rate due to its invasive nature and prolonged duration of disease. According to American Cancer Society (ASC), around 22,240 women are expected to be diagnosed with ovarian cancer, and around 14,070 deaths are expected from the disease in 2018.

Furthermore, introduction of new drugs has propelled the poly adenosine diphosphate ribose polymerase market growth. For instance, the U.S. Food & Drug Administration approved 3 PARP inhibitors—Olaparib, Rucaparib, and Niraparib. These drugs are a potential alternative that aid in treatment of ovarian and other cancers after paclitaxel.

Moreover, combination of these PARP inhibitors with other therapies such as monoclonal antibodies is under research. For instance, in May 2018, TESARO, Inc.—an oncology-focused biopharmaceutical company— announced collaboration with Genentech—a member of the Roche Group—to evaluate the combination of the PD-L1 antibody— Atezolizumab (TECENTRIQ), the MEK inhibitor cobimetinib (COTELLIC), and TESARO’s PARP inhibitor ZEJULA (Niraparib) — in patients with platinum-sensitive ovarian cancer. In April 6, 2018, the U.S. Food and Drug Administration (FDA) approved Rubraca (rucaparib) tablets --manufactured by Clovis Oncology Inc.—for the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in adult patients.

Get PDF for more Professional and Technical insights@

https://www.coherentmarketinsights.com/insight/request-sample/2029

Poly Adenosine Diphosphate Ribose Polymerase Market Regional Insights

North America and Europe are expected to witness significant growth in the poly adenosine diphosphate ribose polymerase market over the forecast period. Increasing demand for approved drugs, owing to high prevalence of various types of cancer is expected to facilitate growth of the market, in the U.S. For instance, according to American Cancer Society (ASC), around 164,690 new cases are expected to be diagnosed with prostate cancer in 2018.

New product launches and robust pipeline of PARP inhibitors is expected to boost the North America, and Europe PARP inhibitors market growth over the forecast period. For instance, Clovis Oncology launched Rubraca (Rucaparib) in 2016, and Tesaro, Inc. launched Zejula (Niraparib) in 2017. Moreover, Lynparza (Olaparib) manufactured by AstraZeneca Plc was approved by the U.S. Food & Drug Administration for the treatment of germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer in January 2018.

Download the PDF brochure: https://www.coherentmarketinsights.com/insight/request-pdf/2029

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Visit our news Website:https://www.coherentwire.com

Ureteral Stents Market - Regional Insights And Major Key Players Like Applied Medical

Ureteral stents are small tubes inserted into the ureter to treat or prevent a blockage that prevents the flow of urine from the kidney to the bladder.

Ureteral Stents Market - Regional Insights And Major Key Players Like Applied Medical, Allium Medical, Bard Medical, B.Braun, Boston Scientific, Cook Medical

Ureteral stents are small tubes inserted into the ureter to treat or prevent a blockage that prevents the flow of urine from the kidney to the bladder. Ureteral stents are flexible in nature and approximately 10 inches in length. The most common application of ureteral stents is the treatment of kidney stones. Other applications include stricture (abnormal narrowing of the ureter), and tumors pushing the ureter, leading to a blockage. Moreover, swollen, inflamed, or damaged ureteral tubes in need of healing can have a stent placed to keep the kidney draining during the healing process.

The global ureteral stents market size was valued at US$ 492.6 million in 2017 and is expected to witness a CAGR of 5.7% over the forecast period (2018 – 2026).

Get PDF for more Professional and Technical insights@

https://www.coherentmarketinsights.com/insight/request-sample/2172
Increasing prevalence kidney related disorders is expected to drive the ureteral stents market revenue

Rising prevalence of urolithiasis worldwide owing to changes in lifestyle such as lack of physical activity and dietary habits is the major factor driving the ureteral stents market revenue. Urolithiasis is a common urologic problem and constitutes a significant burden on the health care system. According to the National Health and Nutrition Examination Survey (NHANES) 2003 report, the prevalence of urolithiasis has increased over the last three decades in the U.S. and projected to experience economic burden, with an additional value of US $1.24 billion per year by 2030.

Along with elderly and adult population, kidney stones also affect children of all ages. According to the Journal of Urology 2015 data, ureteral stent placement is the most common procedures performed in approximately 20% of children with stones. The weighted average annual cost of care for pediatric urolithiasis is US $220 million per year.

Urinary incontinence (UI) is also a significant health problem worldwide with increasing geriatric population rate. It has a large economic and social impact on individuals and nation. According to the European Urology 2012 report, the Epidemiology of Lower Urinary Tract Symptoms (EpiLUTS) reported relatively high UI prevalence rates of 13.3% for men and 30.3% for women in the United Kingdom, Sweden, and the U.S.

Ureteral Stents Market - Regional Insights

On the basis of region, the global ureteral stents market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America and Europe are expected to foresee significant growth in 2026 owing to increased number of urological surgeries, increasing prevalence of kidney stones and presence of major industry players. According to a European Urology study of 2012, in the U.S., kidney stone affects 1 in 11 people, and it is estimated that approximately 600,000 Americans suffer from urinary stones every year.

Asia Pacific ureteral stents market is expected to grow at highest CAGR due to increasing obesity and diabetes patient population prone to kidney disorders and developing healthcare infrastructure in the region. According to a research study published in Current Science journal 2005 data, in India, nearly 12% of patient had urinary stones and out of which 50% may end up with loss of kidney functions.

Download the PDF brochure: https://www.coherentmarketinsights.com/insight/request-pdf/2172

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Visit our news Website:https://www.coherentwire.com